[Does anti-estrogen therapy after estrogen receptor analysis have value in palliative therapy of hepatocellular carcinoma?].
Kreysel
C
C
Abteilung Innere Medizin I, Medizinische Klinik und Poliklinik, Tübingen.
Porschen
R
R
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000737:chemistry / Q000188:drug therapy*; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D008535:Megestrol / Q000008:administration & dosage / Q000009:adverse effects; D010166:Palliative Care; D011960:Receptors, Estrogen / Q000032:analysis / Q000187:drug effects*; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D013629:Tamoxifen; D008535:Megestrol